Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS trial of rivaroxaban with or without aspirin in coronary or peripheral artery disease
NL-OMON47095Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban, aspirin and pantoprazole in coronary arteriosclerosis, arteriosclerosis obliterans and atherosclerosis, sponsored by Bayer. Primary endpoints: Composite of myocardial infarction, stroke, or cardiovascular death, Modified International Society on Thrombosis and Haemostasis major bleeding and 1 more. Started Jul 2013; status: active, not recruiting.
02
Drugs
rivaroxabanaspirinpantoprazole
03
Conditions
coronary arteriosclerosisarteriosclerosis obliteransatherosclerosis
Beyond the preview
Go deeper on NL-OMON47095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47095.